Received Date: July 25, 2017; Accepted Date: August 04, 2017; Published Date: August 10, 2017
Citation: Tintore M, Colome G, Santas J, Espadaler J (2017) Gut Microbiota Dysbiosis and Role of Probiotics in Infant Colic. Arch Clin Microbiol. Vol. 8 No. 4:56 doi:10.4172/1989-8436.100056
Copyright: © 2017 Tintore M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Infant colic or excessive crying syndrome is a behavioral syndrome in 1- to 5-month-old infants involving long periods of inconsolable crying and fussing in otherwise healthy infants. Its etiology is unclear, but evidence regarding the implications of the infant gut microbiota is rising in importance.
In this short review, we aim to expose recent findings on alterations in the microbiota of colicky infants which could trigger or facilitate infant colic, and summarize the clinical and mechanistical evidence of several probiotic formulations for the management of infant colic.
The observed increase in the relative abundance of Enterobacteria in colicky babies may facilitate intestinal hypersensitivity due to their endotoxins, while also increasing the amount of intestinal gas, and thus, bloating and digestive discomfort. Also, an association between infant colic and a decrease in the relative abundance of protective bacterial groups such as bifidobacteria or lactobacilli has been pointed out by independent research groups. Therefore, it is not surprising that many clinical trials have explored the effects of supplementing the microbiota of colicky infants with probiotics due to their known effect in modulating gastrointestinal microbiota.
Infant colic or excessive crying syndrome is a behavioral syndrome in 1- to 5-month-old infants involving long periods of crying and hard-to-soothe behavior. The crying bouts occur without obvious cause, so that their unexplained nature is one of the main reasons for caregivers’ concerns . Its etiology is unknown and possibly multifactorial . Because it affects otherwise healthy infants without a specific cause, infant colic has a controverted physiopathology. In addition, it represents an auto-limited syndrome that disappears after the fourth or fifth month of life. For all these reasons, infant colic is classified as a Functional Gastrointestinal Disease (FGID) . The incidence of infant colic has been reported to range from 8% to 20% , and represents the cause of 10-20% of all pediatrician visits in the first 4 months of life .
Infant colic was initially defined in 1954 by Wessel as an excess of crying or paroxystic irritability without an apparent cause, for more than three hours a day, occurring more than three days a week in three consecutive weeks . However, different concerns were risen regarding this definition, as in daily practice a noticeable population of infants shows an abnormal and unexplained crying profile despite not perfectly fitting Wessel’s criteria. Subjective assessment of crying time was also found to be dependent on the cultural environment of the patient, being subjected to a high variability. For this reason, Wessel’s criteria have been abandoned and the international association for FGIDs, known as the Rome Foundation, has reached a consensus definition of colic as “Recurrent and prolonged periods of infant crying, fussing, or irritability reported by caregivers that occur without obvious cause and cannot be prevented or resolved by caregivers” . This new definition is also a consequence of the high interest displayed by the pediatrician community in identifying this pathology, to investigate and provide adequate treatment.
Colicky bouts are more frequent in the late afternoon or evening, starting suddenly and being intense and often high pitched . Moreover, ‘colicky infants’ are usually very unsettled, fussy or irritable or may show signs of pain (e.g. drawing up knees or arching the back) . Colic is often a serious issue for parents, as excessive crying leads to parental exhaustion and anxiety, with negative consequences such as: difficulties to concentrate, loss of patience, feelings of incompetence, fear of harming the child, early cessation of breastfeeding and reduction of face-to-face interaction with their child [8,9].
Etiology of infant colic and role of gut microbiota
A variety of causes for infant colic have been suggested, including abnormal gastrointestinal function, immaturity of the gut, spastic colon, accumulation of gas, allergic problems and lack of sufficient parent-to-child interaction (Table 1) [2,6,10]. Despite this unclear and possibly multifactorial etiology, studies by independent research groups have correlated alterations in gut microflora with infant colic [11-16]. This consideration has been growing in importance since the early observations of lower counts of intestinal lactobacilli and bifidobacteria in colicky infants compared to healthy ones [17,18].
|Factorsintrinsictotheinfant||Immaturity of the intestinal tract and of theepithelialbarrier|
|Microbial imbalance in the gut microbiota|
|Immature gastrointestinal function (motility, bileacidmechanisms)|
|Accumulation of gas|
|Alterations in gut hormones|
|Laststage in thedevelopmental “crying curve” of healthyinfants|
|Increasing maternal age|
Table 1 Possible factors implicated in the ethiopathology of infant colic.
As a result of the aforementioned studies, the microbiota profile of colicky infants can start to be delineated. First, omics studies conducted by different means (e.g. microarrays, metagenomic analysis) have reported a reduction in overall microbiota diversity compared to healthy infants [12,19]. Second, particular alterations comprising a reduction in the proportions of Bifidobacteria [20,21], Bacteroides  and lactobacilli [14,15,20-22], and an increase of Clostridium, Staphylococcus and specially of Enterobacteria such as Escherichia, Shigella, Klebsiella or Enterobacter have been found [11-13,15-19,23].
Implication of microbiota disturbances in the symptoms of infant colic
Lower microbiota diversity and stability in the first weeks of life may lead to changes in the metabolome of gut microbiota, the ensemble of gut microbiota by-products which influence human health [24,25]. In turn, changes in bacterial metabolome can alter the speed of intestinal transit, facilitating an accumulation of gas causing general digestive discomfort [11,14,26]. Also, deregulation of motor function could result in spasmodic bowel movements, leading to pain. Additionally, a less diverse gut microbiota has been associated with higher levels of calprotectin, a known biomarker of gut inflammation .
As described above, relative abundance of opportunistic and commensal Enterobacterial species seem to increase in infant colic in comparison to healthy infants [12,21]. These bacteria are known to produce gas as a result of their metabolism , which could facilitate bloating and digestive discomfort in colicky babies . Moreover, lipopolysaccharide (LPS) molecules (also known as endotoxins) from Enterobacteria are especially proinflammatory, compared to LPS from other common gut Gramnegative bacteria such as Bacteroides . Inflammatory effect of LPS is mediated by Toll-like receptors, and is known to reduce visceral sensory and pain thresholds (allodynia) both in animal models and in humans [29-31]. By this mechanism, a higher relative abundance of Enterobacteria could facilitate a state of low-grade inflammation and increased visceral sensitivity in colicky infants.
In contrast, evidence suggests that a high proportion of Bifidobacterium and Lactobacillus in the infants microbiota is protective against colicky crying and fussing [12,20]. This protective effect might be related with the fact that mucosal Lactobacillus are able to induce the expression of antiinflammatory genes , improving gut function and motility and exerting a reduction of visceral pain [33,34]. In addition, lactobacilli and bifidobacteria may protect against colic by modulating immune response . Alterations in gut microbiota of colicky infants are summarized in Table 2. Importantly, some factors related to the intestinal microbiota are age-related, which could help explain why infant colic resolves spontaneously around 4 to 6 months of age : First, bile acids represent a key environmental factor modulating gut bacteria at high taxonomic levels, and overall bile acid metabolism is altered during the first months of life (as demonstrated by the fact that cholic to chenodeoxycholic acids ratio in duodenum and bile acid levels in serum are increased during the first months of life). Second, the overall diversity of the intestinal microbiome has been described to increase in an age-related manner during the first months of life, and increased diversity is known to make ecosystems more resistant to perturbations by opportunistic organisms (such as Enterobacteria in the gut).
|Microbiotaalteration||Implication in infantcolic|
|Lowmicrobiotadiversity and stability: changes in metabolome[12,14,19]||Alterations in intestinal transit|
|Higherlevels of calprotectin: inflammation|
|↑Enterobacteriaceae[12,21]||Gas accumulation: bloating and digestivediscomfort|
|Pro-inflammatory and hyperalgesiareactionto LPS|
|↓Bifidobacterium[12,52]||Immune response modulation|
|↓Lactobacillus[12,52]||Expression of anti-inflammatory genes|
Table 2 Alterations in gut microbiota of colicky infants that may be implied in the ethiopathology of infant colic.
Treating infant colic with probiotics
Since an effective solution for excessive crying is not available as of today, it represents an unmet clinical need and there is a high interest in understanding its physiopathology to provide the best available treatment. Because of the evidence of microbiota changes in colicky infants, some probiotic formulations have been studied for the management of infant colic, as summarized in Table 3. The studies have focused mainly on the reduction of crying time as a primary outcome of baby’s discomfort.
|BifidobacteriumlactisBB-12 + S. termophilus||Saavedra et al. 2004 ||Randomized, double-blind, placebo-controlled study. Prophylactic intervention||180
|Crying and fussing behavior (reported by parents)||Significantly lower reported incidence of colic in the probiotic group|
|Lactobacillus reuteriDSM 17938||Savino et al. 2010 ||Randomized, double-blinded, placebo-controlled study||46
|Crying time||Reduction in crying time in the probiotic group after 21 days|
|Responders rate (50% reduction in crying time)||Significantly higher in the L. reuterigroup|
|Gut microbiota||Significant increase in fecal lactobacilli
Reduction in fecal Escherichia coliand ammonia in the L. reuterigroup
|Szajewska et al. 2013 ||Randomized, double-blinded, placebo-controlled study||80
|Responders rate (50% reduction in crying time)||Significantly higher in the probiotic group on days 7, 14, 21 and 28|
|Crying time||Significantly reduced in the probiotic group|
|Parental perception of colic severity||Significant reduction already on day 7|
|Family quality of life||Significant improvement already on day 7|
|Roos et al. 2013||Randomized, double-blinded, placebo-controlled study||29
|Responders rate (50% reduction in crying time)||Significantly higher responders rate in the probiotic group|
|Microbiota composition||Very high inter-individual variability
↑ Bacteroidetesand genusBacteroidesin the responders group on day 21 vs. day 0
|Sung et al. 2014 ||Randomized, double-blinded, placebo-controlled study||167
FF + BF
|Crying time||Significantly higher reduction in the placebo group, especially fussing in formula-fed infants|
|Responders rate (50% reduction in crying time)||No significant differences|
|Sleep duration of infants||Significant less sleep in the probiotic group (P=0.04)|
|Maternal mental health||No significant differences|
|Family functioning||No significant differences|
|Parent quality of life||No significant differences
Significant improvement in both groups at 6 months
|65||Fecal microbiota diversity||No significant differences|
|Colonization with E. coli||No significant differences|
|102||Calprotectin||No significant differences between groups
Lower levels in the responders group after 1 month
|Mi et al. 2015 ||Observational randomized, placebo-controlled study||42
|Number of responders||Significantly higher in the probiotic group (100% vs. 15.7% in the placebo group)|
|Crying time||Significant difference between groups already at day 7 (higher after 4 weeks)|
|Parent satisfaction||Significantly higher in the probiotic group since the first week|
|Maternal depression||Improved significantly in the probiotic group since the first week|
|Chau et al. 2015 ||Randomized, double blinded, placebo-controlled study||52
|Crying time||Significantly shorter in the probiotic group
Significant reduction in the probiotic group vs. placebo
|Responders rate (50% reduction in crying time)||Significantly higher in the probiotic group at day 21|
|Lactobacillus rhamnosusGG||Pärtty et al. 2015 ||Randomized, double-blinded, placebo controlled study||30
FF + BF
|Daily crying (crying diary)||No differences at the end of the study|
|Parents subjective report of daily crying||Lower number of crying days in the probiotic group and higher rate of responders|
|Fecal calprotectin||No significant change|
|Microbiota changes||No statistical differences in microbiota composition
Significant increase in different Bifidobacterium species
|Fatheree et al. 2016 ||Randomized, double-blinded, placebo-controlled pilot study (LGG+ formula)||20
|Crying time||No differences|
|Microbiota changes||No differences in diversity (erratic evolution)
No differences at the genus level
Significant increase in L. rhamnosus
|Fecal calprotectin||No significant differences between groups|
|Cytokine levels||No significant differences between groups|
|Tregs levels||No significant differences between groups|
|Bifidobacterium breveBR03+ B. breveB632||Giglione et al. 2016 ||Randomized, double-blinded, placebo-controlled study. Prophylactic intervention||60
FF + BF
|Reduction in crying time||No significant effects in the full population of the study
Significant reduction of crying time vs. placebo in the formula-fed group only, after 3 months of treatment
|PediococcuspentosaceusCECT 8330 + BifidobacteriumlongumCECT 7894||Santas et al. 2015 ||Randomized, double-blinded, placebo-controlled pilot study||20
FF + BF
|Crying time||Trend towards greater reduction in crying time in the probiotic group compared to placebo, after 14 days|
|Tintore et al. 2017 ||Randomized, double-blind placebo-controlled pilot study||10
FF + BF
|Microbiota diversity||Increase in overall microbiota diversity in probiotic (inversely correlated to crying time in the overall study population)
|Changes in genus associated to infant colic||Reduction in relative abundance of Enterobacteria(mostly of Escherichia/Shigella) and ofStaphylococcus, compared to placebo|
|Changes in genus associated to a protective effect||Significant increase in relative abundance of Bifidobacterium|
|Lactobacillus casei, L. rhamnosus,
L. acidophilus, Streptococcus thermophilus, Bifidobacteriumbreve, B. infantis
|Kianifar et al. 2014 ||Randomized, double-blinded, placebo controlled study||45
|Responders rate (50% reduction in crying time)||Significantly higher in the probiotic group at days 7 and 30|
|Crying time||Significant reduction in the probiotic group at days 7 and 30|
|Symptom resolution||Significantly higher in the probiotic group at day 7, loss of significance at day 30|
|Weight gain||No significant changes at the end of the intervention|
Table 3 Comparison of the different effects of probiotics on infant colic described by clinical trials. Since all studies reported good tolerability and absence of side effects, these are not included in the table. FF: Exclusively or predominantly formula-fed; BF: Exclusively or predominantly breast-fed.
In an early double-blind, randomized, placebo-controlled study including 180 healthy infants aged 3-24 months, prophylactic administration of a standard milk-based formula containing a strain of Bifidobacterium lactis BB-12 and an unspecified strain of Streptococcus thermophilus resulted in a reduction of the incidence of colic, compared to controls . The study represented one of the firsts proofs of the important role of Bifidobacteria as potential probiotics for preventing infant colic, but to our knowledge, no therapeutic studies have assessed the effectiveness of this combination as a treatment of infant colic after the onset of the inconsolable crying behavior.
Subsequently, Lactobacillus reuteri DSM 17938 has been one of the most studied probiotic strains for treating infant colic. Several small studies in predominantly breast-fed colicky infants have consistently reported a significant effect on infant colic vs. controls [37-40] and, according to meta-analysis, the effects were most evident after 21 days of supplementation . However, a randomized study on a larger population including both breastfed and formula-fed colicky infants reported conflicting results, due to a lack of significant difference in responder rate in the overall population (P=0.23), and a significant increase in crying and especially fussing in the subgroup of formula-fed infants (79 minutes on average, P=0.005) [42,43]. Following these studies, the latest World Gastroenterology Organization guidelines on probiotics indicate that L. reuteri DSM 17938 may be effective for breastfed infants with colic, but at this stage, the probiotic cannot be recommended for treating infantile colic in formulafed infants, nor can be routinely used to prevent infantile colic .
The well-known probiotic strain Lactobacillus rhamnosus GG, while being strongly supported for the treatment of acute diarrhea in children , has not reached positive results for the treatment of baby colic in clinical trials. In a first study, diaryverified crying time did not reach a statistical difference upon L. rhamnosus GG supplementation, despite parental subjective assessment of crying suggesting some effectiveness . Of note, this study replicated the finding that Bifidobacteria relative abundance was higher in healthy controls than in colicky infants. A more recent study also reported a lack of efficacy of LGGsupplemented formula with respect to the control one, and little impact on the microbiota composition and on inflammation was observed . These results add to the growing evidence that probiotic effects are strain-specific and condition-specific, as suggested by WGO guidelines .
More recently, a combination of Bifidobacteria – B. breve BR03 and B. breve B632 – has shown a significant reduction in crying time in a subgroup of formula-fed infants after 3 months of prophylactic treatment . However, no significant differences were observed for the full population including breastfed infants. As observed in the study with B. lactis BB-12 and S. termophilus , these results suggest Bifidobacteria may be useful for infantile colic and support the preventive use of the specific strains studied against infant colic in formula-fed infants, but are not sufficient to confirm their effectiveness as a treatment for colicky babies.
Pediococci are round-shaped bacteria belonging to the Lactobacillus group . A probiotic formula including strains Pediococcus pentosaceus CECT 8330 and Bifidobacterium longum CECT 7894 showed a significant trend towards a greater reduction in daily crying time in just 14 days, in a pilot RCT comparing to placebo (p=0.083). The study included both breastfed and formula-fed colicky infants, and in vitro data suggest that the mechanism of action for the probiotic formula may be ascribed to an antagonistic effect against Enterobacteria and a capacity to counteract the pro-inflammatory effect of their endotoxin on the immune cells . Clinical studies with larger sample sizes are required to validate these findings. However, findings are further supported by an additional study on the observed changes in the microbiome after the supplementation with said probiotic strains compared to placebo . More precisely, this study reports an increase in α-diversity in the probiotic group, which correlated with a reduction in the total crying time in the full study population. Also, an increase in Bifidobacterium and a decrease in species belonging to the Enterobacteriaceae family was observed in probiotic-treated infants compared to placebotreated ones. Noteworthy, these results are in agreement with the in vitro studies on the antagonistic effects of the probiotic strains used , as well as with observational evidence on the relationship between infant colic and microbiome diversity, Enterobacterial abundance and Bifidobacterial abundance [12,19].
Finally, symbiotic formulas have also been assessed in the management of infant colic, showing promising results. A mixture of fructooligosaccharides (FOS) and seven unspecified probiotic strains of the species Lactobacillus casei, L. rhamnosus, L. bulgaricus, Streptococcus thermophilus, Bifidobacterium breve, and B. infantis significantly improved symptoms in colicky babies in comparison to placebo [51,52]. Positive effects where observed already on day 7; however, the positive effect of the probiotic vs. placebo had disappeared after 30 days of treatment. In addition, the fact that the probiotic strains were not specified hinders the subsequent replication of this study.
Effective management of infant colic, a condition that severely impacts family quality of life, represents an unmet medical need. Specific changes in gut microbiome have been described in colicky babies, affecting overall diversity and relative abundance of specific bacterial groups such as Enterobacteria, Bifidobacteria and Lactobacilli. In this regard, several clinical trials report evidence of the usefulness of some probiotics to treat this condition. Importantly, not all probiotics studied appear to be effective, and some seem to depend on the infant’s feeding (breastfed vs. formula-fed) for their effectiveness. Further evidence about validated mechanisms of action and randomized clinical studies with larger sample sizes are needed to confirm the benefits of this approach.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : September 14, 2019